Availability of STI Testing & Treatment Products

Purpose

To provide timely information about shortages related to STI testing and treatment products.

Blister pack of capsules and a caution sign.

NOTICE

  • Visit the for information on all current and resolved drug shortages and discontinuations reported to the U.S. Food & Drug Administration (FDA).
  • Notify DSTDP (stdshortages@cdc.gov) of any shortage or low inventories of STI treatments in your jurisdiction so CDC can continue monitoring treatment availability.

Bicillin L-A®

On July 10, 2025, King Pharmaceuticals, a subsidiary of Pfizer, of specific referenced lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension). Further details and priority actions for health departments and healthcare providers are available from the Dear Colleague Letter.

On 1/16/2024, the FDA announced that they have (benzathine benzylpenicillin injection, powder, for suspension). See more in this CDC letter. See more in this CDC letter. , (Benzathine Benzylpenicillin Tetrahydrate) Powder and diluent for suspension for injection, has also been allowed since July of 2024.

Bicillin L-A® is the first-line recommended treatment for syphilis and the only recommended treatment option for some patients.

CDC continues to monitor the situation and will post updates as needed.

Print
Content Source:
National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention; About Division of STD Prevention